CN110573162A - 靶向前列腺素e2及其受体的药物与应用 - Google Patents
靶向前列腺素e2及其受体的药物与应用 Download PDFInfo
- Publication number
- CN110573162A CN110573162A CN201880028018.9A CN201880028018A CN110573162A CN 110573162 A CN110573162 A CN 110573162A CN 201880028018 A CN201880028018 A CN 201880028018A CN 110573162 A CN110573162 A CN 110573162A
- Authority
- CN
- China
- Prior art keywords
- pge2
- vascular
- receptor
- injury
- functional fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种调节对象中血管重构的方法,包括给予对象有效量的能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质;本发明还提供了能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质在制备用于调节对象中血管重构的药物中的应用;本发明还提供了用于调节对象中血管重构的制品,其包含能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017102933609 | 2017-04-28 | ||
CN201710293360 | 2017-04-28 | ||
PCT/CN2018/085035 WO2018196870A1 (zh) | 2017-04-28 | 2018-04-28 | 靶向前列腺素e2及其受体的药物与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110573162A true CN110573162A (zh) | 2019-12-13 |
Family
ID=63919464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880028018.9A Pending CN110573162A (zh) | 2017-04-28 | 2018-04-28 | 靶向前列腺素e2及其受体的药物与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110573162A (zh) |
WO (1) | WO2018196870A1 (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0753527A1 (en) * | 1994-03-23 | 1997-01-15 | Ono Pharmaceutical Co., Ltd. | Prostaglandin e receptor |
CA2520347A1 (en) * | 2003-04-02 | 2004-10-21 | Nexmed Holdings, Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
-
2018
- 2018-04-28 WO PCT/CN2018/085035 patent/WO2018196870A1/zh active Application Filing
- 2018-04-28 CN CN201880028018.9A patent/CN110573162A/zh active Pending
Non-Patent Citations (2)
Title |
---|
ANDERS LUNDEQUIST等: "Prostaglandin E2 Exerts Homeostatic Regulation of Pulmonary Vascular Remodeling in Allergic Airway Inflammation", 《THE JOURNAL OF IMMUNOLOGY》 * |
HUIFENG HAO等: "Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury", 《ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018196870A1 (zh) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition | |
Song et al. | Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1 | |
McCollum et al. | Angiotensin-(1–7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1 | |
Yoon et al. | The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis | |
US9808501B2 (en) | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome | |
Yin et al. | SDF-1α involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice | |
Vinh et al. | Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice | |
EP2493497A2 (en) | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome | |
WO2015035199A1 (en) | Neem compositions used for the treatment of cancer | |
Tai et al. | Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux | |
US7959918B2 (en) | Methods for treating vascular disease | |
Wu et al. | Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition | |
Zhang et al. | In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis | |
Saber-Moghaddam et al. | The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation | |
JPWO2006134692A1 (ja) | Ramp2を標的とする血管構造の安定化剤及び血管新生剤 | |
JPWO2006134692A6 (ja) | Ramp2を標的とする血管構造の安定化剤及び血管新生剤 | |
Moreira et al. | Synthetic apolipoprotein AI mimetic peptide 4F protects hearts and kidneys after myocardial infarction | |
US9457013B2 (en) | Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor | |
He et al. | Krüppel-like factor 15 modulates CXCL1/CXCR2 signaling-mediated inflammatory response contributing to angiotensin II-induced cardiac remodeling | |
US20110275571A1 (en) | Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia | |
Ichihara et al. | Inhibition of ischemia-induced angiogenesis by benzo [a] pyrene in a manner dependent on the aryl hydrocarbon receptor | |
Chen et al. | Glucocorticoid ameliorates early cardiac dysfunction after coronary microembolization and suppresses TGF-β1/Smad3 and CTGF expression | |
Chen et al. | Synergic effect of combined cyclosporin and melatonin protects the brain against acute ischemic reperfusion injury | |
US10272133B2 (en) | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome | |
Holder et al. | The importance of biological sex in cardiac cachexia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191213 |